Drug Trial Radar · NCT06564324
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
Last checked: Nov 20, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
194
Planned (sponsor's estimate)
Start
Nov 27, 2024
Primary completion
Jan 2029
Study completion Sep 2030
Sponsor
- Lead sponsor
- Nuvation Bio Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, randomized, open-label, comparative, multicenter, international study for NSCLC patients whose tumor tissue exhibits ROS1 fusion positivity (i.e., ROS1+) and who have not previously received an ROS1-targeted TKI (i.e., ROS1-TKI-naïve). Approximately 194 ROS-1 TKI- naïve ROS1+NSCLC patients will be randomized in a 1:1 ration to one of 2 study arms: * Arm A: Taletrectinib monotherapy at 600 mg once daily (QD); * Arm B: Crizotinib monotherapy at 250 mg twice daily (BID). Each cycle duration will be 28 days. Participants will be stratified by the presence of intracranial metastases at baseline (Yes versus No) and prior chemotherapy use for locally advanced or metastatic disease (Yes versus No). For the purposes of stratification, prior chemotherapy is defined as completion of ≥1 cycle of chemotherapy in the locally advanced or metastatic setting. Participants will be treated until they experience progressive disease (PD) assessed by the BIRC, intolerable toxicity, or another discontinuation criterion is met. Crossover from control group (crizotinib) to taletrectinib is also permitted, at the Investigator's discretion with the Sponsor's approval, for qualifying participants who have experienced objective progression confirmed by the BIRC.
Conditions
- Non Small Cell Lung Cancer
Interventions
TaletrectinibDrug
Approximately 194 ROS-1TKI- naïve ROS1+NSCLC patients will be randomized in a 1:1 ration to one of 2 study arms: Arm A: Taletrectinib monotherapy at 600 mg once daily (QD); Arm B: Crizotinib monotherapy at 250 mg twice daily (BID). Each cycle duration will be 28 days. Participants will be treated until they experience progressive disease (PD) assessed by the blinded Independent Review Committee (BIRC), intolerable toxicity, or another discontinuation criterion is met.
CrizotinibDrug
Approximately 194 ROS-1TKI- naïve ROS1+NSCLC patients will be randomized in a 1:1 ration to one of 2 study arms: Arm A: Taletrectinib monotherapy at 600 mg once daily (QD); Arm B: Crizotinib monotherapy at 250 mg twice daily (BID). Each cycle duration will be 28 days. Participants will be treated until they experience progressive disease (PD) assessed by the blinded Independent Review Committee (BIRC), intolerable toxicity, or another discontinuation criterion is met. Crossover from control group (crizotinib) to taletrectinib is also permitted, at the Investigator's discretion with the Sponsor's approval, for qualifying participants who have experienced objective progression confirmed by the BIRC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- PFS (Assessed by BIRC)Time frame: About 49 months
Locations
29 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China · Recruiting
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Not yet recruiting
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China · Recruiting
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China · Recruiting
The First Affiliated Hospital of Guangdong Pharmaceutical University
Guangzhou, Guangdong, China · Recruiting
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China · Recruiting
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China · Recruiting
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China · Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Not yet recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Recruiting
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Recruiting
Jiangsu Province Hospital
Nanjing, Jiangsu, China · Recruiting
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China · Recruiting
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China · Recruiting
The First Hospital of China Medical University
Shenyang, Liaoning, China · Recruiting
Linyi Cancer Hospital
Linyi, Shandong, China · Recruiting
Cancer Hospital of Shandong First Medical University
Jinan, Shangdong, China · Recruiting
Shanghai East Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China · Recruiting
Shanxi Cancer Hospital
Taiyuan, Shanxi, China · Recruiting
The First Affiliated Hospital of Xi'an Jiaotong University
Xi’an, Shanxi, China · Recruiting
West China Hospital of Sichuan University
Chengdu, Sichuan, China · Recruiting
Tianjin Cancer Hospital
Tianjin, Tianjin Municipality, China · Recruiting
Yunnan Cancer Hospital
Kunming, Yunnan, China · Not yet recruiting
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.